Clin2
NCT06927297Possibly a fitRecruiting

Safety study of a mitochondrial vaccine for advanced solid tumors

Advanced Solid Tumor MalignanciesAdvanced Solid Malignancies

Part of Cancer clinical trials.

This early-phase trial tests a new type of cancer vaccine designed to help your immune system attack tumors. It is for people with advanced solid tumors who have run out of standard options.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
12 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must be between 18 and 75 years old.
  • You have an advanced solid tumor (like lung or colorectal cancer) that standard treatments haven't helped, or you can't take them.
  • You should be in reasonably good health, as measured by a performance score (able to care for yourself and out of bed more than half the day).
  • Your blood counts, liver, kidney, and heart function must meet certain safe levels.
  • You cannot have other cancers (except fully treated skin, bladder, or early cervical cancers), active autoimmune disease, or serious infections like hepatitis or HIV.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07567222Recruiting· Phase 1
Vaccine therapy for advanced solid tumors

This study tests a new therapeutic vaccine designed to help your immune system fight advanced solid cancers. You would receive vaccine injections alongside standard cancer care if your cancer has progressed despite previous treatments.

Chengdu, Sichuan
NCT06878612Recruiting· Phase 1
Personalized tumor cell vaccine for advanced solid tumors

This trial tests a new vaccine made from your own tumor cells to see if it can help your immune system fight the cancer. It is for people with advanced solid tumors that have not responded to other treatments.

Chengdu, Sichuan
NCT07583654Recruiting· Phase 1
Testing a New mRNA Cancer Treatment for Advanced Solid Tumors

This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.

Chengdu, Sichuan
NCT05749627Recruiting
Vaccine for advanced cancers using your tumor’s targets

This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.

Nanchang, Jiangxi
NCT07182435Not yet recruiting· Early Phase 1
Personalized mRNA vaccine for advanced solid tumors

This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.

Shenzhen, Guangdong
NCT06682117Recruiting
A study of a personalized vaccine for advanced solid tumors

This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.

Shanghai, Shanghai Municipality

Hear when a new Advanced Solid Tumor Malignancies trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.